CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Tianjin Chase Sun Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin New Technology Industrial Park
Wuqing Development Zone,Hi-tech Zone
Phone: +86 2259623217p:+86 2259623217 TIANJIN, TNJ  301700  China Ticker: 300026300026
Business Summary
Tianjin Chase Sun Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of drugs. The Company's main businesses include Chinese medicine formula granules, finished drugs, medical devices, raw materials and excipients, medical health services and smart supply chain of drugs and devices. The Company's finished drugs include Xuebijing Injection, low molecular weight heparin calcium injection, moxifloxacin hydrochloride sodium chloride injection, enoxaparin sodium injection and others. Medical device products are mainly electronic medical devices, including blood oxygen series, home health and primary care. The raw materials and excipients business focuses on the research and development and production of heparin sodium and low molecular weight heparin series raw materials. The Company conducts its businesses in the domestic and foreign markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board WenyuanWu 54 4/1/2024 4/1/2024
Vice Chairman of the Board, General Manager WujunLan 48 4/1/2024 12/29/2011
Finance Director, Executive Deputy General Manager, Director WuSun 54 4/1/2024 4/24/2019
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 5,910 (As of 12/31/2023)
Outstanding Shares: 3,004,154,837 (As of 9/30/2024)
Shareholders: 122,300
Stock Exchange: SHE
Fax Number: +86 2259675226


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025